MX2014009015A - Premezcla de potasio de raltegravir amorfo estable y proceso para la preparacion de la misma. - Google Patents

Premezcla de potasio de raltegravir amorfo estable y proceso para la preparacion de la misma.

Info

Publication number
MX2014009015A
MX2014009015A MX2014009015A MX2014009015A MX2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A
Authority
MX
Mexico
Prior art keywords
preparation
stable amorphous
raltegravir potassium
amorphous raltegravir
potassium premix
Prior art date
Application number
MX2014009015A
Other languages
English (en)
Inventor
Makrand Avachat
Surinder Kumar Arora
Dnyaneshwar Tukaram Singare
Amol Dattatreya Galande
Purna Chandra Ray
Dilip Gopalkrishna Saoji
Girij Pal Singh
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2014009015A publication Critical patent/MX2014009015A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a una premezcla de potasio de Raltegravir amorfo estable, método para prepararla y composición farmacéutica de la misma.
MX2014009015A 2012-01-25 2013-01-25 Premezcla de potasio de raltegravir amorfo estable y proceso para la preparacion de la misma. MX2014009015A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN72KO2012 2012-01-25
PCT/IB2013/050643 WO2013111100A1 (en) 2012-01-25 2013-01-25 Stable amorphous raltegravir potassium premix and process for the preparation thereof

Publications (1)

Publication Number Publication Date
MX2014009015A true MX2014009015A (es) 2014-12-08

Family

ID=47754907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009015A MX2014009015A (es) 2012-01-25 2013-01-25 Premezcla de potasio de raltegravir amorfo estable y proceso para la preparacion de la misma.

Country Status (12)

Country Link
US (1) US20150328215A1 (es)
EP (1) EP2806857A1 (es)
JP (1) JP2015504913A (es)
KR (1) KR20140114406A (es)
CN (1) CN104093400A (es)
AU (1) AU2013213255A1 (es)
BR (1) BR112014018247A8 (es)
CA (1) CA2863575A1 (es)
MX (1) MX2014009015A (es)
RU (1) RU2014134257A (es)
WO (1) WO2013111100A1 (es)
ZA (1) ZA201405247B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3119773A1 (en) * 2014-03-21 2017-01-25 Mylan Laboratories Ltd. A premix of crystalline raltegravir potassium salt and a process for the preparation thereof
CN104146949A (zh) * 2014-08-29 2014-11-19 宁夏泰瑞制药股份有限公司 一种延胡索酸泰妙菌素预混剂及其制备方法
TWI829098B (zh) 2015-01-02 2024-01-11 美商梅拉洛伊卡公司 細菌組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318140T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamid- hemmer der hiv-integrase
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
CN101161244A (zh) * 2006-10-13 2008-04-16 上海世康特制药有限公司 尼莫地平片剂及其制备方法
ES2549387T3 (es) * 2009-06-02 2015-10-27 Hetero Research Foundation Procedimiento de preparación de raltegravir potásico amorfo
WO2010143207A1 (en) * 2009-06-11 2010-12-16 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
WO2011024192A2 (en) * 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
CA2795157C (en) * 2010-04-01 2015-11-24 Teva Pharmaceutical Industries Ltd. Raltegravir salts and crystalline forms thereof
WO2011148381A1 (en) * 2010-05-25 2011-12-01 Hetero Research Foundation Salts of raltegravir

Also Published As

Publication number Publication date
US20150328215A1 (en) 2015-11-19
BR112014018247A8 (pt) 2017-07-11
JP2015504913A (ja) 2015-02-16
WO2013111100A1 (en) 2013-08-01
AU2013213255A1 (en) 2014-08-07
ZA201405247B (en) 2015-12-23
RU2014134257A (ru) 2016-03-20
KR20140114406A (ko) 2014-09-26
AU2013213255A9 (en) 2016-06-16
WO2013111100A9 (en) 2014-08-14
CN104093400A (zh) 2014-10-08
EP2806857A1 (en) 2014-12-03
BR112014018247A2 (es) 2017-06-20
CA2863575A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
WO2012156998A3 (en) Amorphous mirabegron and processes for crystal forms of mirabegron
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MD20150091A2 (ro) Compuşi antivirali
IN2015KN00262A (es)
MX2011008262A (es) Espiroamidas sustituidas como moduladores de b1r:.
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
MX370649B (es) Proceso para la preparacion de teneligliptina.
IN2015KN00323A (es)
MX2015005891A (es) Formas polimórficas de suvorexant.
MY195343A (en) A Novel Phtalazinone Derivatives and Manufacturing Process Thereof
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
MX2016008369A (es) Composicion farmaceutica que incluye palonosetron.
WO2013164839A3 (en) Amorphous form of apixaban, process of preparation and compositions thereof
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2014068586A3 (en) Solid oral compositions of tolvaptan
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
EP2742946A4 (en) PROCESS FOR THE PRODUCTION OF PYROSTEGIA VENUSTA DERIVATIVES, PYROSTEGIA VENUSTA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
MX2014009015A (es) Premezcla de potasio de raltegravir amorfo estable y proceso para la preparacion de la misma.
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
IN2014DN09451A (es)
EP2575465A4 (en) Raltegravir SALTS
GB201021287D0 (en) A stable composition of HOCI, a process for its production and uses thereof
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.